1. Home
  2. ENSG vs SYRE Comparison

ENSG vs SYRE Comparison

Compare ENSG & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo The Ensign Group Inc.

ENSG

The Ensign Group Inc.

N/A

Current Price

$180.84

Market Cap

10.4B

Sector

Health Care

ML Signal

N/A

Logo Spyre Therapeutics Inc.

SYRE

Spyre Therapeutics Inc.

N/A

Current Price

$104.02

Market Cap

8.7B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ENSG
SYRE
Founded
1999
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Hospital/Nursing Management
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.4B
8.7B
IPO Year
2007
2015

Fundamental Metrics

Financial Performance
Metric
ENSG
SYRE
Price
$180.84
$104.02
Analyst Decision
Buy
Strong Buy
Analyst Count
5
18
Target Price
★ $225.80
$122.53
AVG Volume (30 Days)
370.9K
★ 1.0M
Earning Date
10-27-2026
11-03-2026
Dividend Yield
★ 0.14%
N/A
EPS Growth
★ 14.06
N/A
EPS
★ 5.11
N/A
Revenue
★ $5,057,841,000.00
N/A
Revenue This Year
$16.82
N/A
Revenue Next Year
$12.68
N/A
P/E Ratio
$36.85
★ N/A
Revenue Growth
★ 18.72
N/A
52 Week Low
$141.58
$21.63
52 Week High
$218.00
$110.18

Technical Indicators

Market Signals
Indicator
ENSG
SYRE
Relative Strength Index (RSI) 52.68 63.52
Support Level $167.76 $93.45
Resistance Level $185.69 $103.16
Average True Range (ATR) 5.84 4.50
MACD 0.53 1.01
Stochastic Oscillator 56.79 99.10

Price Performance

Historical Comparison
ENSG
SYRE

About ENSG The Ensign Group Inc.

Ensign Group Inc provides post-acute healthcare services in the United States. Its regional subsidiaries oversee skilled nursing, assisted living, home health and hospice, mobile ancillary, and urgent care operations. Medicare and Medicaid programs contribute majority of revenue received for Ensign's services. The firm operates through two segments, Skilled services, and Standard Bearer. The skilled services segment includes the operation of skilled nursing facilities and rehabilitation therapy services. The Standard Bearer segment comprises of properties owned by the company through its captive REIT and leased to skilled nursing and assisted living operations. The majority of the revenue is generated from the skilled services segment.

About SYRE Spyre Therapeutics Inc.

Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.

Share on Social Networks: